Specific laboratory methodologies achieve higher Model for Endstage Liver Disease (MELD) scores for patients listed for liver transplantation

Liver Transplantation

Volumn 10, Issue 8, 2004, Pages 995-1000

  Trotter, James F ^a   Brimhall, Brad ^b   Arjal, Russ ^a   Phillips, Charles ^c  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c Carolinas Medical Center NorthEast   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; CREATININE; PROTHROMBIN; THROMBOPLASTIN;

ADULT; ARTICLE; BILIRUBIN BLOOD LEVEL; CALCULATION; CLINICAL ARTICLE; CLINICAL LABORATORY; COLORIMETRY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIAGNOSTIC KIT; FEMALE; HOSPITAL LABORATORY; HUMAN; INTERMETHOD COMPARISON; INTERNATIONAL STANDARD UNIT; LIVER FAILURE; LIVER TRANSPLANTATION; MALE; MATHEMATICAL MODEL; PHLEBOTOMY; PRIORITY JOURNAL; PROTHROMBIN TIME; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; THROMBOPLASTIN TIME; TREATMENT INDICATION;

BILIRUBIN; CREATININE; HUMANS; LIVER FAILURE, ACUTE; LIVER TRANSPLANTATION; MODELS, BIOLOGICAL; PROTHROMBIN TIME; WAITING LISTS;

EID: 4544300925     PISSN: 15276465     EISSN: None     Source Type: Journal    
DOI: 10.1002/lt.20195     Document Type: Article

References (14)

1. Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, et al. Model for end-stage liver disease (MELD) and allocation of donor liver. Gastroenterology 2003;124:91-96.
2. MELD scores were calculated using the United Network for Organ Sharing website, www.unos.org/resources/MeldPeldCalculator.asp?index=98 (accessed October 18, 2003).
3. MELD score = 10 (0.957 ln [creatinine, mg/dL] + 0.378 ln [bilirubin, mg/dL] + 1.12 ln [INR] + 0.643), where laboratory values less than 1.0 are set to 1.0 for purposes of the MELD score calculation and the maximum serum creatinine considered within the MELD score equation is 4.0 mg/dL.
4. Hirsh J, Poller L. The international normalized ratio. Arch Intern Med 1994;154:282-288.
5. WHO Expert Committee on Biological Standardization. 33rd report. Geneva, Switzerland: World Health Organization: 1983. Technical Report Series No. 687.
6. Robert A, Chazouilleres O. Prothrombin time in liver failure: time, ratio, activity percentage, or international normalized ratio. Hepatology 1996;24:1392-1394.
7. Kovacs MH, Wong A, MacKinnon K, Weir K, Keeney M, Boyle E, Cruickshank M. Assessment of the validity of the INR system for patients with liver impairment. Thromb Haemost 1994;71: 727-730.
8. Denson KWE, Reed SV, Haddon ME, Woodhams B, Brucato C, Ruiz J. Comparative studies of rabbit and human recombinant tissue factor reagents. Thromb Res 1999;94:255-261.
9. Hedner U, Erhardtsen E. Hemostatic disorders in liver disease. In: Schiff ER, Sorrell MF, Maddrey WC, eds. Diseases of the liver. Philadelphia: Lippincott Williams and Wilkins, 2003: 625-635.
10. Organ Procurement and Transplantation Network. http://www.optn.org/latestData/rptData.asp (accessed, April 11, 2004).
11. van den Besselaar AM, Houbouyan-Reveillard LL, Aillaud MF, Denson KW, Droulle C, Johnston M, et al. Multicenter evaluation of lyophilized and deep-frozen plasmas for assignment of the International Normalized Ratio. Thromb Haemost 1999;82: 1451-1455.
12. Grau E, Tenias JM, Olaso MA, Ferrando I, Juan MT, Pastor E, et al. Monitoring oral anticoagulant treatment from plasma stored for up to 48 hours and frozen plasma. Haematologica 1999;84:633-636.
13. Woodhams B, Girardot O, Blanco MJ, Colesse G, Gourmelin Y. Stability of coagulation proteins in frozen plasma. Blood Coagul Fibrinolysis. 2001;12:229.
14. Jazbik C, Couto CG, Gray TL, Kociba G. Effect of storage conditions on hemostatic parameters of canine plasma obtained for transfusion. Am J Vet Res 2001;62:734-735.